HomeConference
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

Business Development Conference 2006

Sponsors

Platinum Sponsor


VISCARDI
 

Gold+ Sponsor


The Trout Group
 

Gold Sponsor


Roche
 

Silver Sponsors


Genzyme
 


Nomura Code
 

up

Exclusive Berlin Conference Catalysed
New Partnerships Between Pharma & Biotech Companies

Berlin 13-14 December: European Small & Medium-sized biopharmaceutical companies had the opportunity to network with counterparts from the larger pharmaceutical companies at a private Business Development Event, organised by the industry associations European Biopharmaceutical Enterprises (EBE) and BIO Deutschland.

Despite the increasing costs, falling output and failure of some new technologies in the European biotechnology R&D landscape, in recent years the start-up rate of new enterprises has increased and the growth of existing European companies has accelerated. Alliances with midsize and big pharma have become a more and more important aspect in European biotech business plans.

With this in mind, the event reviewed how to make European biotech companies more attractive to US and global partners and what are the successful strategies for the future of European biopharmaceutical companies.

Executives from key biotech, pharmaceutical companies, private equity and VC firms shared their experience, concrete case-studies and advice on what should or should not be done in developing biotech company businesses. The conference also analysed the business management and financing practices in the US versus Europe, new exit trends in those regions and the different business models available.

"Biotechnology is not only important for the economy" said Dr. Peter Heinrich, CEO MediGene AG, President BIO Deutschland and EBE Board Member, "not only because of the thousands of people that we employ, but is also essential to the larger pharmaceutical companies which use biotech companies as a source for innovation and finally, let’s not forget, the patients waiting for novel medicines."

The event attracted more than 85 CEOs and senior executives from (bio)pharmaceutical companies, private equity and venture capital companies from around Europe and USA. The exclusive setting of the conference helped participants learn, network and do business. Further to the extremely positive feedback received from attendees, EBE and BIO Deutschland are planning to hold a 2nd edition in 2007, in Germany.

News

July 2008

June 2008

May 2008

April 2008

March 2008

February 2008

January 2008